Maria Winqvist
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maria Winqvist has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Anders Österborg
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
5 shared publicationsJeanette Lundin
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
4 shared publications- Lotta Hansson
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
4 shared publications Anna Asklid
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
3 shared publicationsAgnes Mattsson
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
2 shared publicationsMarzia Palma
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 10 August 2020
- Published by Wiley in British Journal of Haematology
- Vol. 191 (3) , 426-432
Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
Summary: Bendamustine + rituximab (BR) is the current first‐line standard‐of‐care for chronic lymphocytic leukaemia (CLL) in fit patients aged 66–70 years, whereas chlorambucil + CD20 antibody is recommended in older patients with co‐morbidities. This retrospective real‐world study investigated whether risk‐adapted BR was safe and effective in elderly patients. All 141 CLL patients in the Stockholm region (diagnosed from 2007 to 2016, identified from regional registries) who had received BR as first (n = 84) or later line (n = 57) were analysed. Median age was 72 years, 49% had Binet stage C, 40% had Cumulative Illness Rating Scale (CIRS) score ≥ 6, 20% Eastern Cooperative Oncology Group (ECOG) score 2. None had del(17p). Only 15% of patients aged ≥80 years received full‐dose bendamustine and 65% of them postponed rituximab until cycle 2. Corresponding numbers in patients 73–79 years were 21% and 36% and in P < 0·022) equally distributed between age subsets. ECOG, immunoglobulin heavy chain variable region (IGHV) mutational status and cytogenetics, but not treatment line and age, were significant factors on progression‐free survival (PFS) in multivariate analysis. Infections and neutropenia/thrombocytopenia (≥grade 3) were similar across age subgroups. In summary, BR was well tolerated even in patients ≥80 years, with similar efficacy and safety as in less old patients, provided that carefully adapted dosing was applied.
- 10 August 2020
- Published by Wiley in British Journal of Haematology
- Vol. 191 (3) , 426-432
Open AccessRisk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
Summary: Bendamustine + rituximab (BR) is the current first‐line standard‐of‐care for chronic lymphocytic leukaemia (CLL) in fit patients aged 66–70 years, whereas chlorambucil + CD20 antibody is recommended in older patients with co‐morbidities. This retrospective real‐world study investigated whether risk‐adapted BR was safe and effective in elderly patients. All 141 CLL patients in the Stockholm region (diagnosed from 2007 to 2016, identified from regional registries) who had received BR as first (n = 84) or later line (n = 57) were analysed. Median age was 72 years, 49% had Binet stage C, 40% had Cumulative Illness Rating Scale (CIRS) score ≥ 6, 20% Eastern Cooperative Oncology Group (ECOG) score 2. None had del(17p). Only 15% of patients aged ≥80 years received full‐dose bendamustine and 65% of them postponed rituximab until cycle 2. Corresponding numbers in patients 73–79 years were 21% and 36% and in P < 0·022) equally distributed between age subsets. ECOG, immunoglobulin heavy chain variable region (IGHV) mutational status and cytogenetics, but not treatment line and age, were significant factors on progression‐free survival (PFS) in multivariate analysis. Infections and neutropenia/thrombocytopenia (≥grade 3) were similar across age subgroups. In summary, BR was well tolerated even in patients ≥80 years, with similar efficacy and safety as in less old patients, provided that carefully adapted dosing was applied.
- 1 September 2017
- Published by Elsevier in Molecular Immunology
- Vol. 89, 203
Monitoring of hemolytic activity of serum during alemtuzumab/ofatumumab therapy of chronic lymphocytic leukemia
- 1 September 2017
- Published by Elsevier in Molecular Immunology
- Vol. 89, 203
Monitoring of hemolytic activity of serum during alemtuzumab/ofatumumab therapy of chronic lymphocytic leukemia
- 5 July 2017
- Published by Wiley in British Journal of Haematology
- Vol. 182 (4) , 590-594
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease‐negativity in the bone marrow of poor‐prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections – Results from a phase I study
- 5 July 2017
- Published by Wiley in British Journal of Haematology
- Vol. 182 (4) , 590-594
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease‐negativity in the bone marrow of poor‐prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections – Results from a phase I study
- 28 November 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (5) , 1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia – a population-based study from a well defined geographical region between 2003 and 2013
Real-world data is important for comparison when new orphan drugs are evaluated in non-controlled phase 2 trials in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The S...
- 28 November 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (5) , 1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia – a population-based study from a well defined geographical region between 2003 and 2013
Real-world data is important for comparison when new orphan drugs are evaluated in non-controlled phase 2 trials in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The S...
- Open Access
- 4 November 2016
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 66 (1) , 91-102
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
This phase I–II study explored safety, immunomodulatory and clinical effects of lenalidomide (weeks 1–16) and alemtuzumab (weeks 5–16) in 23 patients with refractory chronic lymphocytic leukemia. Most patients had Rai stage III/IV disease and were heavily pretreated (median 4 prior therapies), and 61% had del(17p)/del(11q). Eleven of 19 evaluable patients (58%) responded, with a median response duration of 12 months (1–29+); time to progression was short in non-responders. Lenalidomide had a narrow therapeutic dose range, 2.5 mg/day was not efficient, and maximum tolerated dose was 5 mg/day. Grade 3–4 neutropenia and thrombocytopenia occurred in 84 and 55%, 30% had febrile neutropenia, and CMV-reactivation requiring valganciclovir occurred in 30% of patients. The frequency of proliferating (Ki67+) CD8+ T cells was increased at week 4, with further increase in both the CD4+ and CD8+ subsets (p < 0.01 and + subset (p < 0.003), while effector cells decreased in both the CD8+ and CD4+ subsets (p < 0.0001 and p < 0.01). The Th1/Th2 balance was unchanged at week 4 but shifted toward a Th2 profile after combination therapy. At end of treatment, the frequency of Th17 and regulatory T cells was reduced (p < 0.01), naïve T cells decreased, and effector memory T cells increased (p < 0.05 and p < 0.01). Granzyme B+ T cells increased at 30-week follow-up (p < 0.05). PD-1 expression was unaffected. In conclusion, low-dose lenalidomide and alemtuzumab induced major perturbations of T cells, including increased proliferative activity and cytotoxic potential.
- 4 November 2016
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 66 (1) , 91-102
Open AccessPhase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
This phase I–II study explored safety, immunomodulatory and clinical effects of lenalidomide (weeks 1–16) and alemtuzumab (weeks 5–16) in 23 patients with refractory chronic lymphocytic leukemia. Most patients had Rai stage III/IV disease and were heavily pretreated (median 4 prior therapies), and 61% had del(17p)/del(11q). Eleven of 19 evaluable patients (58%) responded, with a median response duration of 12 months (1–29+); time to progression was short in non-responders. Lenalidomide had a narrow therapeutic dose range, 2.5 mg/day was not efficient, and maximum tolerated dose was 5 mg/day. Grade 3–4 neutropenia and thrombocytopenia occurred in 84 and 55%, 30% had febrile neutropenia, and CMV-reactivation requiring valganciclovir occurred in 30% of patients. The frequency of proliferating (Ki67+) CD8+ T cells was increased at week 4, with further increase in both the CD4+ and CD8+ subsets (p < 0.01 and + subset (p < 0.003), while effector cells decreased in both the CD8+ and CD4+ subsets (p < 0.0001 and p < 0.01). The Th1/Th2 balance was unchanged at week 4 but shifted toward a Th2 profile after combination therapy. At end of treatment, the frequency of Th17 and regulatory T cells was reduced (p < 0.01), naïve T cells decreased, and effector memory T cells increased (p < 0.05 and p < 0.01). Granzyme B+ T cells increased at 30-week follow-up (p < 0.05). PD-1 expression was unaffected. In conclusion, low-dose lenalidomide and alemtuzumab induced major perturbations of T cells, including increased proliferative activity and cytotoxic potential.
- Open Access
- 19 May 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (12) , 1573-1580
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Ibrutinib, a Bruton's tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine healthcare are commonly observed in oncology. We report here real-world results for 95 poor-prognosis Swedish patients treated with ibrutinib in a compassionate-use program. Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included between May 2014 and May 2015. Median age; 69 years, 63% had del(17p)/TP53 mutation, 65% had Rai stage III/IV, 28% had lymphadenopathy ≥10cm. Patients received ibrutinib 420 mg once-daily until progression. At median follow-up of 10.2 months, overall response rate was 84% (consistent among subgroups) and 77% remained progression-free. Progression free survival and overall survival were significantly shorter in patients with del(17p)/TP53 mutation (p=0.017 and p=0.027, log-rank test); no other factor was significant in Cox's multivariate regression analysis. Ibrutinib was well tolerated. Hematomas occurred in 46% of patients without any major bleeding. Seven patients had Richter transformation. This real-world analysis on consecutive chronic lymphocytic leukemia patients from a well-defined geographical region shows efficacy and safety of ibrutinib similar to that of pivotal trials. Yet, del(17p)/TP53 mutation remains a therapeutic challenge. Since not more than half of our patients would have qualified for the pivotal ibrutinib trial (RESONATE), our study emphasizes that real-world results should be carefully considered onwards regarding new agents and new indications in chronic lymphocytic leukemia.
- 19 May 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (12) , 1573-1580
Open AccessReal-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Ibrutinib, a Bruton's tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine healthcare are commonly observed in oncology. We report here real-world results for 95 poor-prognosis Swedish patients treated with ibrutinib in a compassionate-use program. Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included between May 2014 and May 2015. Median age; 69 years, 63% had del(17p)/TP53 mutation, 65% had Rai stage III/IV, 28% had lymphadenopathy ≥10cm. Patients received ibrutinib 420 mg once-daily until progression. At median follow-up of 10.2 months, overall response rate was 84% (consistent among subgroups) and 77% remained progression-free. Progression free survival and overall survival were significantly shorter in patients with del(17p)/TP53 mutation (p=0.017 and p=0.027, log-rank test); no other factor was significant in Cox's multivariate regression analysis. Ibrutinib was well tolerated. Hematomas occurred in 46% of patients without any major bleeding. Seven patients had Richter transformation. This real-world analysis on consecutive chronic lymphocytic leukemia patients from a well-defined geographical region shows efficacy and safety of ibrutinib similar to that of pivotal trials. Yet, del(17p)/TP53 mutation remains a therapeutic challenge. Since not more than half of our patients would have qualified for the pivotal ibrutinib trial (RESONATE), our study emphasizes that real-world results should be carefully considered onwards regarding new agents and new indications in chronic lymphocytic leukemia.